NCT05776888View on ClinicalTrials.gov

Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

Active, not recruitingOBSERVATIONAL
Enrollment

106

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Relapsing Multiple Sclerosis
Interventions
OTHER

Ofatumumab

There is no treatment allocation. For both cohorts, only patients that have received Ofatumumab treatment for at least 3 months prior to inclusion in the study will be enrolled.

Trial Locations (14)

1090

Novartis Investigative Site, Vienna

2130

Novartis Investigative Site, Mistelbach

3100

Novartis Investigative Site, Sankt Pölten

4020

Novartis Investigative Site, Linz

4400

Novartis Investigative Site, Steyr

4600

Novartis Investigative Site, Wels

5020

Novartis Investigative Site, Salzburg

6020

Novartis Investigative Site, Innsbruck

8036

Novartis Investigative Site, Graz

9020

Novartis Investigative Site, Klagenfurt

9500

Novartis Investigative Site, Villach

A-4014

Novartis Investigative Site, Linz

A 4020

Novartis Investigative Site, Linz

A 1090

Novartis Investigative Site, Vienna

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY